{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T04:46:14Z","timestamp":1785732374815,"version":"3.56.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Multi-specific drugs play important roles in addressing multi-factorial disease conditions. DR10624 is a first-in-class long acting Fc fusion triple agonist targeting FGF21R, GLP-1R, and GCGR, which has shown promising efficacy in reducing liver fat and triglycerides. Accurate quantification of the intact, pharmacologically active form of DR10624 in serum is essential for reliable pharmacokinetic (PK) characterization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Rabbit monoclonal antibodies that specifically recognize the N- and C-termini regions of DR10624 were developed and strategically paired for precise quantification. An electrochemiluminescence (ECL) based immunoassay was established and rigorously validated in accordance with regulatory guidelines. Additionally, a preclinical pharmacokinetic study in cynomolgus monkeys was performed to compare drug exposure using different assay formats.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Antibody screening successfully identified highly specific rabbit monoclonal antibodies, notably clones 4G7 and 1A12, which selectively bound to the intact N- and C-termini of DR10624 and effectively neutralized its GLP-1\/GCG and FGF21 activities, respectively. Furthermore, the preclinical pharmacokinetic study in cynomolgus monkeys revealed a marked discrepancy between total and intact DR10624 exposure, indicating\n                      <jats:italic>in vivo<\/jats:italic>\n                      instability and underscoring the need to quantify active drug concentrations. The ECL-based immunoassay was successfully validated across a wide concentration range of 5.00\u20131,250 ng\/mL in serum, confirming its accuracy, precision, selectivity, linearity, absence of hook effect, and stability.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The validated dual-monoclonal ECL method provides a robust and specific approach for quantifying intact, bioactive DR10624 in human serum. This assay supports reliable PK assessment in ongoing and future clinical trials, facilitating the continued development of DR10624 for the treatment of MASLD\/MASH, severe hypertriglyceridemia (SHTG), and related metabolic diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1863402","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T04:25:49Z","timestamp":1785731149000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Terminus-specific antibody development and bioanalytical assay validation to quantify active DR10624 in pharmacokinetic studies"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhenxing","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Innovative Drug Discovery and Development, Zhejiang Doer Biologics Co., Ltd.","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Innovative Drug Discovery and Development, Zhejiang Doer Biologics Co., Ltd.","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaofeng","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Innovative Drug Discovery and Development, Zhejiang Doer Biologics Co., Ltd.","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Innovative Drug Discovery and Development, Zhejiang Doer Biologics Co., Ltd.","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Innovative Drug Discovery and Development, Zhejiang Doer Biologics Co., Ltd.","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Innovative Drug Discovery and Development, Zhejiang Doer Biologics Co., Ltd.","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimei","family":"Sheng","sequence":"additional","affiliation":[{"name":"Department of Innovative Drug Discovery and Development, Zhejiang Doer Biologics Co., Ltd.","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanshan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Innovative Drug Discovery and Development, Zhejiang Doer Biologics Co., Ltd.","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"B2","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1111\/jdi.13896","article-title":"Potential of a glucagon-like peptide-1 receptor\/glucose-dependent insulinotropic polypeptide receptor\/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes","volume":"13","author":"Araki","year":"2022","journal-title":"J. Diabetes Investig."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.2174\/0929867311320130004","article-title":"Polypharmacology in a single drug: multitarget drugs","volume":"20","author":"Bolognesi","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"111675","DOI":"10.1016\/j.diabres.2024.111675","article-title":"Incretin-based investigational therapies for the treatment of MASLD\/MASH","volume":"211","author":"Brouwers","year":"2024","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1038\/d41591-023-00055-1","article-title":"Efruxifermin combined with a GLP-1 receptor agonist reduces liver fat in NASH","volume":"29","author":"Carvalho","year":"2023","journal-title":"Nat. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.drudis.2010.01.002","article-title":"The future of non-human primate use in mAb development","volume":"15","author":"Chapman","year":"2010","journal-title":"Drug Discov. Today"},{"key":"B7","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.tem.2024.02.001","article-title":"Current status and future perspectives of FGF21 analogues in clinical trials","volume":"35","author":"Chui","year":"2024","journal-title":"Trends Endocrinol. Metab."},{"key":"B9","volume-title":"Pharmacopoeia of the People\u2019s Republic of China, Part IV,","author":"Commission","year":"2020"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.2337\/dc09-0798","article-title":"Beta-cell-mediated signaling predominates over direct alpha-cell signaling in the regulation of glucagon secretion in humans","volume":"32","author":"Cooperberg","year":"2009","journal-title":"Diabetes Care"},{"key":"B11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fendo.2019.00080","article-title":"Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes","volume":"10","author":"Deacon","year":"2019","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41586-020-2168-1","article-title":"Multispecific drugs herald a new era of biopharmaceutical innovation","volume":"580","author":"Deshaies","year":"2020","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s41573-025-01262-w","article-title":"How multispecific molecules are transforming pharmacotherapy","volume":"24","author":"Deshaies","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"B14","doi-asserted-by":"publisher","first-page":"116318","DOI":"10.1016\/j.jpba.2024.116318","article-title":"Development and validation of bioanalytical assays for the quantification of 9MW2821, a nectin-4-targeting antibody-drug conjugate","volume":"248","author":"Fang","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B15","doi-asserted-by":"publisher","first-page":"S593","DOI":"10.1016\/s0168-8278(25)01598-3","article-title":"FRI-365 DR10624, a novel FGF21R, GCGR, and GLP-1R tri-agonist, demonstrated extraordinary efficacy in B6-Alms1-del mice, a spontaneous MASH model of mice with obesity, hyperglycemia, and dyslipidemia phenotype","volume":"82","author":"Fang","year":"","journal-title":"J. Hepatology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/s0168-8278(25)00422-2","article-title":"LBP-003 DR10624, a first-in-class, FGF21 receptor (FGF21R)\/glucagon receptor (GCGR)\/GLP-1 receptor (GLP-1R) triple agonist rapidly and significantly reduced liver fat in obese subjects with modest hypertriglyceridemia: a 12-week randomized, placebocontrolled, double-blind, multi-center trial","volume":"82","author":"Fang","year":"","journal-title":"J. Hepatology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"35581","DOI":"10.1074\/jbc.M113.512046","article-title":"A novel glucagon-like peptide-1 (GLP-1)\/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice","volume":"288","author":"Gault","year":"2013","journal-title":"J. Biol. Chem."},{"key":"B18","volume-title":"Bioanalytical Method Validation and study Sample Analysis M10","author":"Guideline","year":"2022"},{"key":"B19","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.jhep.2024.04.034","article-title":"FGF21 agonists: an emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond","volume":"81","author":"Harrison","year":"2024","journal-title":"J. Hepatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.3390\/ph16111601","article-title":"The novel tetra-specific drug C-192, conjugated using UniStac, alleviates non-alcoholic steatohepatitis in an MCD diet-induced mouse model","volume":"16","author":"Kim","year":"2023","journal-title":"Pharm. (Basel)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41421-024-00700-0","article-title":"Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide","volume":"10","author":"Li","year":"2024","journal-title":"Cell Discov."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1021\/acs.jproteome.5c00079","article-title":"Differential role of phosphorylation in glucagon family receptor signaling revealed by mass spectrometry","volume":"24","author":"Lamb","year":"2025","journal-title":"J. Proteome Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"10581","DOI":"10.1021\/acs.jmedchem.1c00683","article-title":"Rational multitargeted drug design strategy from the perspective of a medicinal chemist","volume":"64","author":"Li","year":"2021","journal-title":"J. Med. Chem."},{"key":"B24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jpba.2018.07.049","article-title":"Development of a double-antibody sandwich ELISA for rapid detection to C-peptide in human urine","volume":"162","author":"Lv","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/jcp.21675","article-title":"Different roles of N- and C- termini in the functional activity of FGF21","volume":"219","author":"Micanovic","year":"2009","journal-title":"J. Cell Physiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.diabet.2018.09.002","article-title":"Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"45","author":"Mishriky","year":"2019","journal-title":"Diabetes Metab."},{"key":"B27","doi-asserted-by":"publisher","first-page":"103202","DOI":"10.1016\/j.ebiom.2020.103202","article-title":"A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis","volume":"63","author":"Pan","year":"2021","journal-title":"EBioMedicine"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1210\/me.2007-0313","article-title":"betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c","volume":"22","author":"Suzuki","year":"2008","journal-title":"Mol. Endocrinol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3389\/fphar.2015.00205","article-title":"Multi-target pharmacology: possibilities and limitations of the \u201cskeleton key approach\u201d from a medicinal chemist perspective","volume":"6","author":"Talevi","year":"2015","journal-title":"Front. Pharmacol."},{"key":"B30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/B978-0-12-417144-2.00018-4","article-title":"Pharmacokinetics of human therapeutics characterized in nonhuman primates","volume-title":"The Nonhuman Primate in Nonclinical Drug Development and Safety Assessment","author":"Tseng","year":"2015"},{"key":"B31","article-title":"Bioanalytical method validation","year":"2018","journal-title":"Guid. Industry"},{"key":"B32","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jpba.2013.06.005","article-title":"An electrochemiluminescence (ECL)-based assay for the specific detection of anti-drug antibodies of the IgE isotype","volume":"86","author":"Wu","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.febslet.2008.11.023","article-title":"FGF21 N- and C-termini play different roles in receptor interaction and activation","volume":"583","author":"Yie","year":"2009","journal-title":"FEBS Lett."},{"key":"B34","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/j.1747-0285.2012.01325.x","article-title":"Understanding the physical interactions in the FGF21\/FGFR\/beta-Klotho complex: structural requirements and implications in FGF21 signaling","volume":"79","author":"Yie","year":"2012","journal-title":"Chem. Biol. Drug Des."},{"key":"B35","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jpba.2012.05.033","article-title":"Development and validation of sensitive sandwich ELISAs for two investigational nonapeptide metastin receptor agonists, TAK-448 and TAK-683","volume":"70","author":"Yoshida","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B36","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in microsoft excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Programs Biomed."},{"key":"B38","doi-asserted-by":"publisher","first-page":"8881","DOI":"10.1021\/acs.jmedchem.9b00017","article-title":"Rational design of multitarget-directed ligands: strategies and emerging paradigms","volume":"62","author":"Zhou","year":"2019","journal-title":"J. Med. Chem."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1863402\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T04:25:51Z","timestamp":1785731151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1863402\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":35,"alternative-id":["10.3389\/fphar.2026.1863402"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1863402","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"article-number":"1863402"}}